ONCY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Oncolytics Biotech Inc (ONCY) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the stock has potential upside based on analyst ratings and future FDA developments, the lack of significant financial growth, neutral trading sentiment, and absence of strong technical or proprietary trading signals suggest that it is better to hold off on investing right now.
The MACD histogram is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 30.756, and moving averages are converging, showing no clear trend. The stock is trading below the pivot level of 0.911, with key resistance at 1.015 and support at 0.808.
H.C. Wainwright raised the price target to $10 from $5 and maintained a Buy rating, citing confidence in the company's data and potential FDA advancements in cancer treatments.
No recent news or significant trading activity from hedge funds, insiders, or Congress. The stock shows a 70% chance of minor declines in the short term (-0.63% in the next day and -0.74% in the next week).
In Q3 2025, revenue remained at 0 with no YoY growth. Net income improved by 50.90% YoY but remains negative at -$14.4M. EPS improved by 16.67% YoY to -0.14, but the company is not yet profitable.
H.C. Wainwright has increased confidence in the stock due to compelling data and potential regulatory advancements, raising the price target to $10 and maintaining a Buy rating.
